72.29
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$72.28
Aprire:
$72.65
Volume 24 ore:
333.92K
Relative Volume:
0.95
Capitalizzazione di mercato:
$1.66B
Reddito:
$923.71M
Utile/perdita netta:
$84.68M
Rapporto P/E:
18.34
EPS:
3.9419
Flusso di cassa netto:
$182.81M
1 W Prestazione:
-2.17%
1M Prestazione:
-1.77%
6M Prestazione:
-7.40%
1 anno Prestazione:
-21.38%
Ani Pharmaceuticals Inc Stock (ANIP) Company Profile
Nome
Ani Pharmaceuticals Inc
Settore
Telefono
(609) 759-1810
Indirizzo
104 CARNEGIE CENTER DRIVE SUITE 300, PRINCETON, MN
Compare ANIP vs TAK, TEVA, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
ANIP
Ani Pharmaceuticals Inc
|
72.29 | 1.66B | 923.71M | 84.68M | 182.81M | 3.9419 |
|
TAK
Takeda Pharmaceutical Co Adr
|
19.67 | 62.84B | 29.91B | 1.30B | 3.49B | 0.4056 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.50 | 48.40B | 17.53B | 1.58B | 444.18M | 1.3457 |
|
HLN
Haleon Plc Adr
|
10.13 | 44.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
ZTS
Zoetis Inc
|
79.38 | 32.80B | 9.51B | 2.64B | 2.14B | 6.0361 |
|
UTHR
United Therapeutics Corp
|
533.12 | 22.87B | 3.17B | 1.29B | 1.01B | 27.09 |
Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-09-23 | Iniziato | Oppenheimer | Perform |
| 2026-09-09 | Iniziato | Leerink Partners | Outperform |
| 2026-07-17 | Iniziato | Canaccord Genuity | Hold |
| 2025-07-10 | Iniziato | H.C. Wainwright | Buy |
| 2025-03-14 | Iniziato | Jefferies | Buy |
| 2025-03-12 | Iniziato | JP Morgan | Overweight |
| 2024-12-11 | Iniziato | Leerink Partners | Outperform |
| 2024-10-11 | Iniziato | Piper Sandler | Overweight |
| 2024-03-15 | Iniziato | CapitalOne | Overweight |
| 2023-08-22 | Reiterato | H.C. Wainwright | Buy |
| 2023-03-01 | Iniziato | Guggenheim | Buy |
| 2022-09-07 | Iniziato | H.C. Wainwright | Buy |
| 2021-11-02 | Iniziato | Truist | Buy |
| 2020-05-07 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2019-09-12 | Iniziato | Guggenheim | Buy |
| 2019-05-10 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2017-10-16 | Reiterato | Canaccord Genuity | Buy |
| 2017-07-31 | Iniziato | Canaccord Genuity | Buy |
| 2017-02-22 | Downgrade | ROTH Capital | Buy → Neutral |
| 2016-06-23 | Iniziato | Raymond James | Strong Buy |
| 2016-05-24 | Downgrade | Standpoint Research | Buy → Hold |
| 2015-11-13 | Iniziato | Standpoint Research | Buy |
| 2015-09-28 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2015-08-05 | Reiterato | Oppenheimer | Outperform |
| 2015-08-04 | Reiterato | ROTH Capital | Neutral |
| 2015-07-31 | Reiterato | Oppenheimer | Outperform |
| 2015-07-15 | Reiterato | ROTH Capital | Neutral |
| 2015-06-23 | Reiterato | Oppenheimer | Outperform |
| 2015-05-18 | Reiterato | ROTH Capital | Neutral |
| 2015-05-06 | Reiterato | Oppenheimer | Outperform |
| 2015-04-10 | Downgrade | ROTH Capital | Buy → Neutral |
| 2015-02-26 | Reiterato | ROTH Capital | Buy |
| 2015-02-18 | Reiterato | Oppenheimer | Outperform |
Mostra tutto
Ani Pharmaceuticals Inc Borsa (ANIP) Ultime notizie
Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report? - Zacks Investment Research
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar - Zacks Investment Research
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises - Zacks Investment Research
ANI Pharmaceuticals, Inc. (ANIP) Stock Forecasts - Yahoo Finance
Form 4 ANI Pharmaceuticals Inc For: 1 October By Investing.com - Investing.com Nigeria
Ani Pharmaceuticals SVP & CFO Stephen Carey sells $208,050 in stock - Investing.com
ANI Pharmaceuticals, Inc. (ANIP) Stock Forecasts - Yahoo! Finance Canada
ANI Pharmaceuticals (NASDAQ:ANIP) Stock: Insider Stephen Carey Sells 2,850 Shares - MarketBeat
After selling 2,850 shares, ANI Pharmaceuticals (ANIP) CFO holds 168,993 shares. - Stock Titan
Amphastar Pharmaceuticals, Inc. (AMPH) Stock Price, News, Quote & History - Yahoo! Finance Canada
ANI Pharmaceuticals Announces New Fluocinolone Acetonide - GlobeNewswire
Data on an eye implant for chronic eye inflammation will be presented in a late-breaking talk Oct. 9. - Stock Titan
ANI Pharmaceuticals, Inc. (ANIP) Stock Price, News, Quote & History - Yahoo! Finance Canada
Implied Volatility Surging for ANI Pharmaceuticals Stock Options - Yahoo Finance UK
Implied Volatility Surging for ANI Pharmaceuticals Stock Options - TradingView
Implied Volatility Surging for ANI Pharmaceuticals Stock Options - Yahoo! Finance Canada
183,066 Shares of ANI Pharmaceuticals, Inc. $ANIP Acquired by Bank of America Corp DE - MarketBeat
ANIP5868601 Bond Profile: Coupon and Redemption - TradingView
ANI Pharmaceuticals: Cortrophin’s Q4 Test, With Generics Funding The Build (NASDAQ:ANIP) - Seeking Alpha
ANI Pharmaceuticals, Inc. (ANIP) Stock forecasts - Yahoo Finance Singapore
ANI Pharmaceuticals, Inc. (ANIP) Stock Forecasts - Yahoo Finance
Ocular Therapeutix and ANI Pharmaceuticals Stocks Trade Down, What You Need To Know - Yahoo Finance
ANI Pharmaceuticals gets FDA approval for generic everolimus - Investing.com
Oppenheimer initiates ANI Pharmaceuticals stock with Perform rating - Investing.com
ANI Pharmaceuticals Receives FDA Approval for Generic Everolimus Tablets for Oral Suspension - Quiver Quantitative
ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension - Yahoo Finance
ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension - GlobeNewswire
Oppenheimer Initiates ANI Pharmaceuticals at Perform With $85 Price Target - Yahoo Finance
ANI Pharmaceuticals (NasdaqGM:ANIP) Stock Forecast & Analyst Predictions - simplywall.st
ANI Pharmaceuticals (ANIP) Reports Next Week: Wall Street Expects Earnings Growth - Eastern Progress
ANI Pharmaceuticals (ANIP) CEO sells 5,400 shares in pre-set trading plan - Stock Titan
ANI Pharmaceuticals (NASDAQ: ANIP) insider lines up $380,000 stock sale for 2026 - Stock Titan
ANI Pharmaceuticals (ANIP) insider sells 500 shares - Stock Titan
Ani Pharmaceuticals’ Meredith Cook sells $35,395 in common stock - Investing.com
ANI Pharmaceuticals (ANIP) director sells 1,000 shares in planned trade - Stock Titan
VIRGINIA RETIREMENT SYSTEMS ET Al Acquires New Position in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
ANI Pharmaceuticals (NASDAQ: ANIP) director plans $71K share sale - Stock Titan
WINTON GROUP Ltd Takes $4.56 Million Position in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
ANI Pharmaceuticals at Wells Fargo conference: rare disease push gains pace - Investing.com Canada
ANI Pharmaceuticals stock hits 52-week low at 70.03 USD By Investing.com - Investing.com Nigeria
ANI Pharmaceuticals stock hits 52-week low at 70.03 USD By Investing.com - Investing.com South Africa
ETFs Investing in ANI Pharmaceuticals, Inc. Stocks - tradingview.com
ANI Pharmaceuticals (NASDAQ:ANIP) Sets New 52-Week LowTime to Sell? - MarketBeat
ANI Pharmaceuticals stock hits 52-week low at 70.03 USD - investing.com
ANI Pharmaceuticals (NASDAQ:ANIP) Earns Outperform Rating from Analysts at Leerink Partners - MarketBeat
Legal & General Group Plc Buys Shares of 45,075 ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
ANI Pharmaceuticals (ANIP) Appoints Henry Gosebruch To Its Board - Yahoo Finance
ANI Pharmaceuticals to Present at September Investor Conferences - The Manila Times
ANI Pharmaceuticals to Present at September Investor Conferences - Yahoo Finance
Ani Pharmaceuticals Inc Azioni (ANIP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Ani Pharmaceuticals Inc Azioni (ANIP) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. |
Oct 13 '26 |
Sale |
73.59 |
500 |
36,795 |
73,424 |
| CAREY STEPHEN P. | SVP & CFO |
Sep 29 '26 |
Sale |
73.00 |
2,850 |
208,050 |
168,993 |
| Lalwani Nikhil | PRESIDENT & CEO |
Sep 15 '26 |
Sale |
71.00 |
5,400 |
383,400 |
339,089 |
| NIKHIL LALWANI | Director |
Sep 15 '26 |
Proposed Sale |
70.40 |
5,400 |
380,160 |
0 |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. |
Sep 14 '26 |
Sale |
70.79 |
500 |
35,395 |
73,924 |
| JEANNE THOMA | Director |
Sep 11 '26 |
Proposed Sale |
71.46 |
1,000 |
71,460 |
0 |
| Thoma Jeanne | Director |
Sep 11 '26 |
Sale |
71.53 |
1,000 |
71,530 |
26,762 |
| CAREY STEPHEN P. | SVP & CFO |
Aug 31 '26 |
Sale |
72.80 |
2,850 |
207,480 |
171,843 |
| Lalwani Nikhil | PRESIDENT & CEO |
Aug 25 '26 |
Sale |
74.30 |
5,400 |
401,220 |
344,489 |
| NIKHIL LALWANI | Director |
Aug 25 '26 |
Proposed Sale |
74.17 |
5,400 |
400,518 |
0 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):